Mydocalm (Tolperisone Hydrochloride)

Tolperisone Hydrochloride, the active ingredient in Mydocalm, is a centrally acting muscle relaxant presented as an oral tablet for oral use. It is employed to alleviate muscle spasm, musculoskeletal pain, and spasticity associated with neurological disorders. It is marketed across the European Union and is prescribed by physicians for conditions requiring reduction of excessive skeletal muscle tone.

GNH USA supplies Mydocalm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mydocalm (tolperisone hydrochloride) acts on skeletal muscle hyperexcitability and is used in the following clinical situations:

Muscle spasm: reduces involuntary muscle contractions and associated pain. Musculoskeletal pain: alleviates pain related to strain or injury of muscles and joints. Spasticity: improves muscle tone in neurological disorders such as multiple sclerosis or post‑stroke conditions.

Adverse reactions to Mydocalm are generally mild but may occur.

Common Side Effects: - Dizziness - Drowsiness - Nausea - Dry mouth

Serious or Rare Side Effects: - Severe hypotension - Allergic skin reactions (rash, urticaria) - Hepatic enzyme elevation - Agranulocytosis (very rare)

When prescribing Mydocalm, clinicians should consider the following precautions:

Pregnancy: safety category unknown; use only if benefits outweigh risks. Liver impairment: monitor hepatic function and adjust dose if necessary. Elderly patients: start with the lowest effective dose due to increased sensitivity. Concomitant CNS depressants: may enhance drowsiness; monitor closely. Hypotension: observe blood pressure, especially in patients on antihypertensives. Store at below 25°C: keep in the original packaging, protect from moisture.

Mydocalm may interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Other centrally acting muscle relaxants: additive CNS depression. - MAO inhibitors: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may potentiate blood‑pressure‑lowering effect. - CYP3A4 inhibitors (e.g., ketoconazole): may increase tolperisone plasma levels. - Alcohol: can enhance drowsiness and dizziness.